Evidence map›Paper›PMID 39242529›Full record

ArticleTranslational psychiatry2024

Orphan receptor-GPR52 inverse agonist efficacy in ameliorating chronic stress-related deficits in reward motivation and phasic accumbal dopamine activity in mice.

Chenfeng Zhang, Diana Kúkeľová, Hannes Sigrist, Bastian Hengerer, Ramona F Kratzer, Philipp Mracek, Azar Omrani, Moritz von Heimendahl, Christopher R Pryce

Abstract read
In one paragraph

Article in Translational psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chenfeng ZhangPreclinical Laboratory, Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic and University of Zurich, Zurich, Switzerland.
Diana KúkeľováPreclinical Laboratory, Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic and University of Zurich, Zurich, Switzerland.
Hannes SigristPreclinical Laboratory, Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic and University of Zurich, Zurich, Switzerland.
Bastian HengererCNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.ORCID 0000-0002-7811-9795
Ramona F KratzerDepartment of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Philipp MracekDepartment of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Azar OmraniCNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Moritz von HeimendahlCNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.ORCID 0000-0003-3418-8163
Christopher R PrycePreclinical Laboratory, Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic and University of Zurich, Zurich, Switzerland. christopher.pryce@bli.uzh.ch.ORCID 0000-0002-5614-4690

Funding

Boehringer Ingelheim 329941Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 31003A_179381
6 · The paper itself

Abstract

Reward processing dysfunctions e.g., anhedonia, apathy, are common in stress-related neuropsychiatric disorders including depression and schizophrenia, and there are currently no established therapies. One potential therapeutic approach is restoration of reward anticipation during appetitive behavior, deficits in which co-occur with attenuated nucleus accumbens (NAc) activity, possibly due to NAc inhibition of mesolimbic dopamine (DA) signaling. Targeting NAc regulation of ventral tegmental area (VTA) DA neuron responsiveness to reward cues could involve either the direct or indirect-via ventral pallidium (VP)-pathways. One candidate is the orphan G protein-coupled receptor GPR52, expressed by DA receptor 2 NAc neurons that project to VP. In mouse brain-slice preparations, GPR52 inverse agonist (GPR52-IA) attenuated evoked inhibitory postsynaptic currents at NAc-VP neurons, which could disinhibit VTA DA neurons. A mouse model in which chronic social stress leads to reduced reward learning and effortful motivation was applied to investigate GPR52-IA behavioral effects. Control and chronically stressed mice underwent a discriminative learning test of tone-appetitive behavior-sucrose reinforcement: stress reduced appetitive responding and discriminative learning, and these anticipatory behaviors were dose-dependently reinstated by GPR52-IA. The same mice then underwent an effortful motivation test of operant behavior-tone-sucrose reinforcement: stress reduced effortful motivation and GPR52-IA dose-dependently restored it. In a new cohort, GRAB

Indexed as

DopamineDopaminergic NeuronsMotivationNucleus AccumbensRewardStress, PsychologicalAnimalsBehavior, AnimalDisease Models, AnimalMaleMiceMice, Inbred C57BLReceptors, Dopamine D2Receptors, G-Protein-CoupledVentral Tegmental AreaDopamineGpr52 protein, mouseReceptors, Dopamine D2Receptors, G-Protein-Coupled

Identifiers

PMID39242529
PMCPMC11379876

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.